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Fibronectin (FN) is a multi-functional, adhesion protein and involved in multi-steps of the wound healing process. Strong evidence suggests
that FN protein diversity is controlled by alternative RNA splicing; a coordinated transcription and RNA processing that is development-, age-,
and tissue/cell type-regulated. We previously demonstrated that fetal rabbit airway mucosal healing is regenerative and scarless. Expression,
regulation, and biological function of the FN gene and various spliced forms in this model are unknown. Airway and skin incisional wounds were
made in fetal (gestation days 21–23), weanling (4–6 weeks) and adult (>6 months) rabbits. Non-wounded and wounded tissues were collected at
12 h (all age groups), 24 h and 48 h (weanling only) post-wounding. Expression profiles were obtained using mRNA differential display and
cDNAs of interest were cloned, sequenced and validated by real-time PCR. Here, we report two rabbit cDNAs that showed similar expression
patterns after wounding. One encodes a rabbit fibronectin gene, Fn1, and another shares a high sequence homology to a human pre-mRNA
splicing factor, arginine/serine-rich 3 (Sfrs3), coding for a RNA binding protein, SRp20. Both Fn1 and Sfrs3 mRNAs were suppressed in fetal
wounds but induced in postnatal wounds 12 h post-wounding. The increased levels of both Fn1 and Sfrs3 transcripts were sustained up to 48 h in
weanling airway mucosal wounds. The augmentations of the two genes in postnatal airway mucosal wounds were more prominent than that in
skin wounds, indicating that the involvement of Sfrs3 and Fn1 genes in postnatal airway mucosal wounds is tissue-specific. Literature provides
evidence that SRp20 is indeed involved in the alternative splicing of FN and that the embryonic FN variants reappear during adult wound healing.
A connection between the enhanced molecular activity of Sfrs3 and the regulation of the FN gene expression through alternative splicing during
the early events of postnatal airway mucosal wound repair was proposed.
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Subglottic stenosis (SGS) is a major clinical problem in
premature infants following prolonged intubations [1–3] and
in adults following percutaneous dilational tracheotomy [4].
Promotion of airway mucosal wound healing with less or no
scarring remains the best strategy and a research challenge.
One of the most promising potential strategies is to recapitulate
the unique healing capacity of the developing fetus, that is the
fetal skin incisional wounds made in the early gestation heal
more rapidly than adult wounds and they heal in a regenerative
pattern without scar formation [5]. Distinct differences between
fetal and postnatal tissue responses to wounding have been
demonstrated in human and animal models and in several types
of tissues [6,7].
Study of normal skin embryogenesis and comparison
between early scarless and late scarring fetal wounds have
revealed distinct differences in the inflammatory response,
cellular mediators, wound contraction, and extracellular matrix
(ECM) modulators [8]. Tissue-specific wound regeneration or
repair was observed in fetal and postnatal wounds. Fetal
diaphragmatic wounds heal with scar formation [9]. Distinct
tissue-specific profiles of cytokines and growth factors and
associated healing process were observed comparing oral
mucosal and skin wounds [10,11]. Previous studies in variety
of tissues from different species of animals suggest that
exposure to the components in amniotic fluid is not a crucial
determinant in fetal scarless wound repair [12]. We previously
reported that fetal airway mucosal healing is regenerative and
scarless [13]. However, key molecules that govern fetal airway
mucosal scarless wound healing remain largely unknown.
Wound healing process is very complex and involves
multiple events, including homeostasis, angiogenesis, inflam-
mation, epithelialization, granulation, collagen deposition,
fibroplasias, scar formation and tissue remodeling [14].
Fibronectin (FN), an adhesive glycoprotein, is one of the
early expressed molecules found in wounds, involved in
multi-steps of wound healing process and scar formation. FN
is a modulator of various functions including cell attachment,
adhesion and spreading, migration, differentiation, prolifera-
tion, blood clotting, phagocytosis, ECM synthesis and
formation, tissue remodeling and degeneration [15]. FN is
a constituent of the ECM early in embryonic development
[16,17], is involved in the migration of all the major cell
types into the wound site, including fibroblasts, keratino-
cytes, endothelial cells, and macrophages [18], opsonizes
tissue debris after injury [19], and acts as a provisional
matrix for ECM assembly [20]. FN plays a major role in
vocal fold physiology, pathology and wound healing [21]. In
airway, FN regulates the migration of the small airway
epithelial cells [22], fibroblasts [23], and airway smooth
muscle cells [24] and is involved in the beta 1 integrin-
mediated enhancement of human airway smooth muscle
cytokine secretion [25].
FN functional complexity is carried through its protein
diversity, which consists of multiple isoforms, including
plasma FN (pFN, a soluble dimeric form in blood) [26] andcellular FN filaments (cFN, a dimeric or multimeric form at
the cell surface and in ECM) [27]. Upon wounding, FN, as a
major component of the primary ECM, is expressed at high
levels in the wound site. The pFN is released from the alpha-
granulates of platelets that are activated by damaged blood
vessels and the cFN is synthesized locally at the wound site
[28]. FN protein diversity is controlled by alternative pre-
mRNA splicing; a coordinated transcription and RNA proces-
sing [29,30]. All isoforms of Fn are encoded by a single large
gene, Fn1 (50 kb, 50 exons) [31], and have three regions
subject to alternative splicing including extra domain A (EDA,
EIIIA), extra domain B (EDB, EIIIB) and a variable region (V,
IIICS), depending on the cell type and stage of development
[29,32,33]. In human about 20 different mRNA-encoding
protein subunits are produced [34]. The full-length nature of
some variants has not been determined. Alternative splicing
presumably allows a cell to produce the type of FN that is
most suitable for the needs of certain tissue or cellular
functions [35,36]. Nevertheless, development-, age-, and
time-dependent, and tissue-specific expression and regulation
of the FN gene in airway mucosal wound repair have not
previously been reported.
Gene expression is one of the early cellular responses to
wound healing. During wound repair, tissue responses to
wounding feature marked changes in gene expression [37]. A
key issue in understanding the differential molecular mechan-
isms of scarless and scarring airway mucosal wound repair
between fetus and adult is to identify differentially expressed
genes and associated signaling cascades that are preferentially
regulated in a development-, age-, tissue/cell type-, and time-
dependent manner during the early events of the wound
healing process. Therefore, our study goal is to define the
unique gene expression patterns by comparison between fetal
scarless wound healing and postnatal fibrotic wound repair.
From the well-developed model of the fetal and adult rabbit
airway and skin wound healing [13], using mRNA differential
display profiling we isolated numerous genes that were
differentially expressed during wound repair [38,39]. Reasons
for choosing mRNA differential display as a strategy for
differential gene expression profiling are the lack of the
genomic information in this species (rabbit) and the unknown
molecular paths that differentiate the regeneration in the fetal
airway mucosal wounds or the scar formation in postnatal
wounds.
From the differential display generated cDNA pool at
12 h after wounding, we isolated over 600 cDNA fragments
(manuscript in preparation). Among them, one cDNA tag (477
bp) shares high sequence homologies with multiple spliced
transcript variants of a human Fn1 gene. From the same cDNA
pool we also isolated and cloned a pre-mRNA splicing factor,
arginine/serine-rich 3 (Sfrs3), encoding a RNA binding protein,
a serine/arginine-rich protein of 20-KD (SRp20). The molec-
ular activities of the Fn1 and Sfrs3 genes in fetal airway
mucosal and skin wounds are strikingly different from their
postnatal counterparts, suppressed in fetal wounds but induced
in postnatal wounds. FN protein diversity in wound healing
process is known to be modulated by alternative splicing. The
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mucosal wounds in vivo has not been previously described.
Here, we report the identification, isolation and character-
ization of a rabbit Fn1 cDNA, a molecule in provisional ECM
of wounds, and a rabbit arginine/serine-rich 3 (Sfrs3) cDNA
fragment, a pre-mRNA splicing factor, in fetal, weanling, and
adult rabbit airway mucosal and skin wounds during the early
phase of the wound healing process. We hypothesize that
SRp20 is co-regulated with FN and modulates FN gene
expression through alternative splicing during the early events
of postnatal airway mucosal wound repair.
2. Materials and methods
2.1. Animal model
Adult pregnant and non-pregnant Pasteurella-free New Zealand white
rabbits were obtained from a supplier (Hazelton Research Products, Denver,
PA, USA) approved by the United States Department of Agriculture (USDA).
At least 3 animals or fetuses were used in each group (non-wounded and
wounded), including fetus at gestation days 21–23 (term=31 days), weanling
(4–6 weeks) and adult (>6 months) rabbits. Animal maintenance and
experiments were conducted following a protocol approved by the Animal
Research and Care Committee of the Children’s Hospital of Pittsburgh,
Pittsburgh, PA (Animal Welfare Assurance Number: A3617–A3701).
Rabbit airway and skin wounds were produced following well-established
techniques as previously applied in our laboratory [13]. Briefly, anesthesia was
induced with a mix of ketamine–HCl (35 mg/kg) and xylazine–HCl (5 mg/kg)
via intramuscular injection. For fetal surgery in pregnant rabbits, anesthesia was
maintained with a mix of 1–3% halothane, 2% oxygen and 1% nitrous oxide
delivered by spontaneous mask ventilation at a rate of 1 L/min. The abdominal
hair was shaved and the skin was prepared with povidone-iodine. The site for
the incision was treated locally with subcutaneous infiltration of the skin with
2% lidocaine. A lower midline laparotomy incision was made extending from
the umbilicus to the most caudal set of nipples. The size, number and position
of the fetuses were determined by palpation. A surgery was performed on every
second fetus to reduce the risk of the spontaneous abortion and the every other
fetus was left un-wounded for controls. A purse-string suture was placed
through all layers of the uterus and a hysterotomy incision was made within the
borders of the suture. The fetal animal was partially delivered through the
opening to expose the areas intended for wounding and then carefully replaced.
All skin incisional wounds were made on the dorsal skin in an identical pattern
(¨1 cm long). For airway mucosal wounds, midline thyrotomy was made,
followed by cricoidotomy and circumferential mechanical injury of the
subglottic mucosa. Sterile normal saline was added to reconstitute the volume
of the lost amniotic fluid and the purse-string suture was closed in layers with
running sutures. Similar procedures for generating skin and airway mucosal
wounds were applied to weanling and adult rabbits.
After 12 h, a second surgery was carried out to deliver all the fetuses and
the mother was euthanized under a deep anesthesia with an intracardiac
injection of a mix containing sodium pentobarbital (50 mg/kg)/Euthasol (0.2
mL/kg). Non-wounded and wounded airway and skin tissues from individual
age groups were immediately collected, rinsed in cold physiological saline,
rapidly frozen in liquid nitrogen and stored at minus 80 -C. For weanling
rabbits, tissues were also collected at 24 h and 48 h after wounding.
2.2. mRNA differential display
Technical details about mRNA differential display were described in our
previous publication [39] and company’s website (RNAimagei kits,
GenHunter Co., Nashville, TN, USA; http://www.genhunter.com). Briefly,
each tissue was individually homogenized and total RNA was extracted in
TRIzol reagent (GIBCO BRL, Gaithersburg, MD, USA) following the
instructions of the manufacturer. The RNAwas treated with RNase-free DNase
I to reduce the risk of genomic DNA contamination and the RNA integrity wasexamined in 1% agarose/Tris-borate-EDTA (1TBE) gel. RNA samples from
two or three individual rabbits of fetal and postnatal groups at 12 h after
wounding were used for mRNA differential display profiling. Reverse
transcription reaction included 0.2 Ag DNA-free total RNA, a differential
display oligo(dT) primer and MMLV reverse transcriptase. The reaction was
incubated at 65 -C for 5 min, at 37 -C for 60 min, and at 75 -C for 5 min on a
Perkin Elmer 480 thermocycler (Applied Biosystems Inc., Foster City, CA,
USA). The PCR reaction included 2 AL of cDNA, a differential display
oligo(dT) primer and an arbitrary primer, [alpha-33P]-dATP (3000 Ci/mmol)
(ICN Biomedicals Inc., Casta Mesa, CA, USA), and AmpliTaq DNA
polymerase (Perkin Elmer, Norwalk, CT, USA). Low-stringency PCR was
performed for 40 cycles with temperature at 94 -C for 15 s, at 40 -C for 2 min,
and at 72 -C for 2 min on a 9600 thermocycler (Applied Biosystems Inc). PCR
products were size-fragmented side-by-side on a 6% denaturing polyacrylamide
gel (National Diagnostics, Atlanta, GA, USA) for 3.5 h. The gel was dried
under vacuum at 80 -C and exposed to a Kodak XAR-2 film (Scientific
Imaging Systems, Rochester, NY, USA) for 24 h to 48 h. The autoradiogram
with bands showing differential expression was aligned with the gel assisted
with Glogos II Autorad Markers (Stratagene, La Jolla, CA, USA). Differen-
tially expressed bands were excised from the gel and the cDNA was extracted
by ethanol precipitation and centrifugation, and re-amplified by PCR as
previously described [39].
2.3. Cloning and sequencing
PCR products containing cDNAs of interest were purified using Wizard
PCR Preps DNA Purification System (Promega, Madison, WI, USA). The
purified PCR products were cloned using pGEM-T Vector System II
(Promega). Positive colony selection, plasmid DNA preparation and sequenc-
ing were performed as previously described [39]. Sequence analysis was
performed using Sequencher software 4.1 (Gene Codes Co., Ann Arbor, MI,
USA), BLAST program (http://www.ncbi.nlm.nih.gov/BLAST) and Entrez
cross-database search (http://www.ncbi.nlm.nih.gov/entrez) (National Center
for Biotechnology Information, National Library of Medicine, National
Institutes of Health, MD, USA).
2.4. Real-time PCR2.4.1. Gene-specific primers
Primers for the amplification of a rabbit Fn1 fragment (341 bp) were
designed based on the sequence information of a rabbit Fn1 (Ac #AB004811)
(Nishimura, M, 1997, unpublished) at the region of a cDNA coding sequence
(CDS) that shares high sequence homologies across the species (Fig. 3),
including a forward primer (5V-ACC ATA CCT GCC GAATGTAGATGA-3V)
and a reverse primer (5V-CAA CCT CCT CCC GCA CTT TGT GCC-3V).
Primers for the amplification of a rabbit Sfrs3 fragment (187 bp) were designed
based on the sequence information of the human SFRS3 (Ac #NM_003017)
[40] at the CDS region that shares high sequence homologies across the species
(Fig. 6), including a forward primer (5V-CGT GGC CCA CCT CCC TCT TG-
3V) and a reverse primer (5V-AGA AGG ATC GGG ACG GCT TGT GAT-3V).
Primers for the amplification of a 450-bp fragment of the rabbit 18S ribosomal
RNA (rRNA) (Ac #X06778) [41] was designed and used as an endogenous
control for data normalization, including a forward primer (5V-CCG CTA GAG
GTG AAATTC TTG GAC-3V) and a reverse primer (5V-GCATGC CAG AGT
CTC GTT CGT TAT-3V).
2.4.2. Reverse transcription and real-time PCR
Gene expression levels were assessed using real-time PCR as that we
previously described [42]. Briefly, a reverse transcription reaction included 250
ng of DNA-free total RNA pooled from each group, random primers, and
SuperScript II (GIBCO), and was incubated at 25 -C for 10 min, 48 -C for 30
min, and 95 -C for 5 min in a 9600 thermocycler (Applied Biosystems Inc.).
SYBR Green PCR reagents (Applied Biosystems Inc.) were used for PCR
amplification. The PCR reaction (in triplicate) included 5 AL of 10X SYBR
PCR Buffer, 6 AL of 25 mM MgCl2, 4 AL of each dNTPs (blended with 2.5
mM dATP, dGTP and dCTP, and 5 mM dUTP), 2.5 AL of each gene-specific
primer (5 AM), 0.5 AL of AmpErase UNG (0.5 unit), 0.25 AL of AmpliTaq
Gold (1.25 units) and 5 AL of cDNA in a final volume of 50 AL. The conditions
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40 cycles at 95 -C for 15 s, and 60 -C for 1 min in an ABI PRISM 7700
Sequence Detection system (Applied Biosystems Inc.).
2.4.3. Data analysis
The 7700 Sequence Detection Software (Applied Biosystems Inc.) was
used for instrument control, automated data collection, and data analysis.
Relative quantification (fold difference) of the expression levels of each
transcript for each group was calculated using the 2-DDC t method [43]. The
log cDNA copy number of a target gene that was automatically normalized
to the ROX internal passive reference (logDRn) was plotted as a function of
cycle number. The cycle number at which the signal crossed the mid-linear
portion of the log DRn-cycle function was defined as the cycle threshold
(C t) (Fig. 7). Because the input cDNA copy number and Ct are inversely
related, a sample that contains more copies of the template will have a data
line that crosses the Ct at an earlier cycle compared to one containing fewer
copies of the template. The DCt represents the Ct of the target gene norma-
lized to the rabbit endogenous 18S rRNA (DCt =Ct
TargetC t18S rRNA). Rela-
tive quantification (fold difference) of the mRNA expression levels of the




2.5. Search for promoter sequences, transcription factor binding sites
(TFBSs), and transcription factors
Similar expression patterns of the Fn1 and Sfrs3 genes in this model may
suggest that during the wounding process, both genes are transcriptionally
regulated by one (or more) common transcription factor(s). Search for
putative promoter-specific TFBSs and transcription factors for each gene
might reveal conserved regulatory elements that are critical for their co-
expression during wound healing. This task was performed by computation-
based search engines of the Eukaryotic Promoter Database (EPD, Release 82,
http://www.epd.isb-sib.ch) [44], the Searching Transcription Factor Binding
Sites (TFSEARCH, version 1.3, Dr. Yutaka Akiyama) (http://www.cbrc.jp/
research/db/TFSEARCH.html) [45], and the Multi-genome Analysis of
Positions and Patterns of Elements of Regulation (MAPPER) (http://
mapper.chip.org) [46].
3. Results
3.1. Isolation of a rabbit Fn1 cDNA clone
From the differential display generated cDNA pool, we
selected two cDNA tags that were preferentially suppressed
in fetal airway mucosal and skin wounds but induced in
adult wounds. One cDNA (477 bp, Ac #DQ022369) (Fig. 1)
shares a high sequence homology to a fibronectin 1 (Fn1) gene
at 3V-untranslated regions (3V-UTRs) across the species includ-
ing rabbit (98%) (renal cortex, Ac #S80206) [47] (Fig. 2),
human (88%) (FN1 transcript variants 1 and 2, Acs
#NM_212482 and NM_212475) [48], rat (86%) (Ac
#NM_019143) [49], and mouse (84%) (Ac #NM_010233)
[50] (Fig. 3). By comparison of the FN1 CDSs between rabbit
and human, we noticed that the CDSs of the two human FN1
transcript variants are over 7000 bp, whereas the CDS of theFig. 1. Differential display generated rabbit Fn1 cDNA clone sequence (477 bp, Ac
(AP8 and H-T11G) are underlined.previously published rabbit Fn1 is only 303 bp [47]. Our Fn1
clone sequence has an ‘‘aY t’’ switch at the base 125 and one
extra ‘‘g’’ at the base 128 (Fig. 2). These mismatches could be
either generated from sequencing error or tissue-specific. We
are confident about the accuracy of our sequence data because
this clone sequence was generated from 8 independent colonies
(16 sequences using either T7 or SP6 primer) of the clones
derived from the two independent experiments (data not
shown). Since we only isolated partial cDNA sequence at the
3V-UTR, we do not know the full-length nature of this mRNA
and its encoding Fn1 isoform. Based on the sequence
homologies, this rabbit clone is most likely Fn1 transcript
variant 1 or 2 (Fig. 3).
3.2. Isolation of a rabbit Sfrs3 cDNA clone
Another rabbit cDNA fragment (372 bp, Ac #AF401290)
(Fig. 4) showed a similar expression pattern as that of Fn1,
down-regulated in fetal airway mucosal and skin wounds but
up-regulated in postnatal wounds. This clone shares high
sequence homologies to a pre-mRNA splicing factor, arginine/
serine-rich 3 (Sfrs3), encoding RNA binding protein, SRp20
(serine/arginine-rich protein of 20-KD), at the 3V-UTRs across
the species including human (91%) (Ac #NM_003017)
[40] (Fig. 5), dog (91%) (XM_532124) [51], Gecko (91%)
(Ac #AY880406) (Gu X, 2005, unpublished), rat (88%) (Ac
#XM_342107) (NCBI predicted), mouse (88%) (Ac
#NM_013663) (NCBI predicted), and cow (82%)
(Ac #XM_592905) (NCBI predicted) (Fig. 6). Sequence-
based analysis suggests that the clone that was isolated
from our rabbit airway mucosal and skin wounds is indeed
Sfrs3.
3.3. Differential expression of Sfrs3 and Fn1 in airway mucosal
and skin wounds
3.3.1. Reproducibility of the assays
Real-time PCR quantifications of the Sfrs3 and Fn1 gene
transcripts were performed in non-wounded and wounded
airway mucosal samples (in triplicate) of the fetal (Fig. 7a),
weanling (Fig. 7b) and adult (Fig. 7c) rabbits 12 h after injury.
The logarithm of the DRn-normalized cDNA copy number for
transcripts encoding rabbit 18S rRNA (endogenous control),
Fn1 and Sfrs3 were plotted as a function of cycle number. The
overlapping amplification curves for the triplicate runs
demonstrate the reproducibility of the assay. For rabbit 18S
rRNA, the data showed no difference between the respective
curves for the non-wounded and wounded samples. In
contrast, the differences between non-wounded and wounded#DQ022369, this study). Flanking sequences of the differential display primers
Fig. 2. Fn1 sequence homology (98%) between the rabbit cDNA clone (477 bp, Ac #DQ022369, this study) and rabbit renal cortex Fn1 (Ac #S80206) [47]. An
‘‘aY t’’ switch at the base 125 and one extra ‘‘g’’ at the base 128 are shown in bold.
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3.3.2. Non-wounded tissue expression
The abundances of the Sfrs3 and Fn1 mRNAs in non-
wounded skin and airway mucosa were compared among the
three age groups (Fig. 8). The cycle threshold (DCt) was
normalized to the rabbit 18S rRNA of the same tissue of the
same age. The input cDNA copy number and DCt are
inversely related. Sfrs3 mRNA was the most abundantly
expressed in the fetal tissues (airway>skin), followed byFig. 3. Fn1 sequence alignment. Rabbit cDNA clone (477 bp, Ac #DQ022369, this
species including rabbit (renal cortex, 98%) (S80206) [47], Homo sapiens (Hs) (hum
(NM_019143) [49], and mouse (84%) (NM_010233) [50]. Real-time PCR amp
(Nishimura,M, 1997, unpublished).weanling (skin>airway) and the least expressed in adult,
suggesting that the RNA alternative splicing is more active
during fetal development. For the Fn1, there is no significant
difference of the mRNA abundance between fetal and
weanling tissues, whereas Fn1 is the least expressed in adult
tissues, especially in adult skin.
3.3.3. Wounded tissue expression
Quantitative data of the expression generated from the skin
and airway mucosal wounds 12 h after wounding assessed by
real-time PCR were summarized in Fig. 9. The expression levelstudy) shares high sequence homologies to the Fn1 gene at 3V–UTRs across the
an transcript variants 1 and 2, 88%) (NM_212482, NM_212475) [48], rat (86%)
lified fragment (341 bp) is shown against a rabbit Fn1 CDS (AB004811)
Fig. 4. Differential display generated rabbit Sfrs3 cDNA clone sequence (372 bp, Ac #AF401290, this study). Flanking sequences of the differential display primers
(AP6 and H-T11C) are underlined.
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referenced as a fold difference relative to the respective value
measured for the non-wounded control sample of the same age.
Similar expression patterns of the Fn1 and Sfrs3 genes in skin
and airway mucosal wounds were observed. Both genes were
suppressed in fetal wounds but induced in postnatal wounds,
indicating that Fn1 is a potential target of the SRp20 alternative
splicing and/or that the two genes are regulated by conserved
regulatory elements. The suppressed or silenced molecular
activities of the two genes in fetal wounds may suggest a
mechanism that prevents fetal wounds from fibrotic repair. It is
interesting to note that the augmentations of the postnatal
expression of both Fn1 and Sfrs3 genes in airway mucosal
wounds were more prominent than that in skin wounds,
indicating that the involvement of Sfrs3 and Fn1 genes in
postnatal airway mucosal wounds is tissue-specific. In wean-
ling airway mucosal wounds, increased levels (over 2-fold) of
both Fn1 and Sfrs3 transcripts were sustained up to 48 h post-
injury (Fig. 10). Results further suggest that the two genes are
involved in the early events of the postnatal airway mucosal
wound repair.Fig. 5. Sfrs3 cDNA sequence homology (91%) between rabbit (Oryctolagus cunicul
Hs) (Ac #NM_003017) [40,76].3.4. FN1 and SFRS3: predicted promoter sequences,
transcription factor binding sites (TFBSs), and transcription
factors
Search for putative promoter-specific TFBSs for each gene
might reveal conserved regulatory elements that are critical for
their co-expression during wound healing. Since there is no
full-length rabbit cDNA sequence available for either Fn1 or
Sfrs3, we examined the promoter sequences of the human FN1
gene (Ac #EP16038: ccagaggggcgggagggccgtcccatataagccc-
ggctcccgcgctccgACGCCCGCGCC) and the human SFRS3
gene (Ac #EP73723: attccagtatggcgtataaataaaggcgagga-
gaaggcggtggtccgccATTTCGTGGAC). We found that the two
genes do not share a common TFBS. TFBSs for FN1 include
ADR1, Sp1, and STRE, whereas TFBSs for SFRS3 are CdxA,
HSF, TATA, CF2-II, XFD-1, and Pbx-1. Nevertheless, data
from MAPPER search showed 13 predicted transcription
factors that may be shared by FN1 and SFRS3 at the promoter
region of each gene, including ADF-1 (GeneID #47082),
RUNX1 (861), PLAU (5328), XBP1 (7494), CAAT-BOX
(440973), CREB1 (1385), HEN-1 (191666), NFKB1 (4790),us, Oc) clone (372 bp, Ac #AF401290, this study) and human (Homo sapiens,
Fig. 6. Sfrs3 sequence alignment. Rabbit cDNA clone (372 bp, Ac #AF401290, this study) shares high sequence homologies to the Sfrs3 gene at 3V–UTRs across the
species including human (91%) (NM_003017) [40,76], dog (91%) (XM_532124) [51], Gecko (91%) (AY880406) (Gu X, 2005, direct submission and unpublished),
rat (88%) (XM_342107) (NCBI predicted), mouse (88%) (NM_013663) (NCBI predicted), and cow (82%) (XM_592905) (NCBI predicted). A real-time PCR
fragment (187 bp) is shown against human FN1 CDS (NM_003017) [40,76].
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ZFP161 (7541). Therefore, we do not exclude the possibility
that the similar expression patterns of the two genes may be
regulated at the transcription levels by the same transcription
factor(s).
4. Discussion
4.1. Summary of the results and validation of the differential
display and animal model
Using the strategy of the mRNA differential display,
simultaneous comparison of the cDNA tags between fetal
and postnatal rabbit airway mucosal and skin wounds during
the early events of the tissue responses to wounding, we
identified, isolated and cloned two co-expressed cDNA
fragments, Fn1 and Sfrs3, that were selectively suppressed inFig. 7. Real-time PCR. 18S rRNA, Sfrs3 and Fn1 in triplicate samples from the non-w
(a), weanling (b) and adult (c) rabbit 12 h after injury. The logarithmic amplification f
ROX internal passive reference (log DRn) versus cycle number. Cycle threshold (Ct
of the amplification.fetal wounds but induced in postnatal wounds 12 h after injury.
The increased levels of the two genes were sustained in
weanling airway mucosal wounds up to 48 h after wounding.
Both cDNAs share high sequence homologies at 3V-UTRs
across the species including human, rats and mouse. The data
of the cDNA pool generated from this in vivo model confirmed
that the mRNA differential display has a unique ability to
identify gene-specific 3V-UTRs. The 3V-UTR is often gene-,
tissue- and cell type-, gender-, and species-specific [52,53],
indicating that the differential display generated expression
profile could reveal wound-model specific phenotypes. This
feature also provides a great promise for gene therapy using
microRNA targeting. MicroRNAs are small noncoding RNAs
that recognize and bind to partially complementary sites in the
3V-UTRs of target genes and regulate protein production of the
target transcript [54]. The suppression or silencing of the
molecular activities of the two genes in fetal wounds mayounded (gray lines) and wounded (black lines) airway mucosal samples of fetal
unctions were constructed by plotting the cDNA copy number normalized to the
) is defined as a cycle number at which the signal crosses the mid-linear portion
Fig. 8. Real-time PCR. The mRNA abundances of the Sfrs3 and Fn1 genes in non-wounded rabbit skin (white columns) and airway mucosal (black columns) tissues.
The DC t represents the cycle threshold Ct of the target gene normalized to the rabbit 18S rRNA. Input cDNA copy number and the Ct are inversely related.
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repair.
The rabbit Fn1 and Sfrs3 cDNAs share higher sequence
homologies to human’s than any other species, suggesting that
rabbit serves a valuable model relevant to human wound repair,
particularly because of its short period of gestation and size
(easy for housing and fetus surgery), which are preferable to
the study of fetal airway mucosal scarless wound healing.
4.2. Age-dependent and tissue-specific expression of Sftrs3 and
Fn
There are several reasons for us to focus on the Fn and
Sfrs3 gene expression in this report: (1) Fn is one of the early
expressed molecules found in wounds; (2) Fn is one of the
most important molecules in wound healing process as well
as scar formation; (3) potential role of Sfrs3 in mRNA
alternative splicing of Fn1 variants [55,56]; and (4) bothFig. 9. Real-time PCR. Sfrs3 and Fn1 in fetal (white columns), weanling (stripped c
injury. Data were normalized to the rabbit 18S rRNA of the same group and adjusgenes showed similar expression patterns in skin and airway
mucosal wounds, a striking difference between fetal and
postnatal wounds, and tissue-specific augmentations in
postnatal airway mucosal wound compared to skin wounds
(Fig. 9).
In non-wounded airway mucosa, Sfrs3 mRNAwas the most
abundantly expressed in fetal tissues, followed by weanling,
and the least expressed in adults. Our results suggest that the
RNA alternative splicing is more active during fetal develop-
ment. Serine/arginine-rich (SR) proteins serve multiple roles in
the posttranscriptional control of gene expression, including as
regulators of alternative splicing during cell differentiation and
development [57].
In our model at 12 h after wounding, expression levels of
the Fn1 and Sfrs3 were suppressed in fetal airway mucosal and
skin wounds, whereas they were induced in the postnatal
wounds, indicating that Fn1 mRNAs were not active or even
inhibited in fetal wounds 12 h post-wounding. The Fnolumns) and adult (black columns) skin and airway mucosal wounds 12 h after
ted to a 0-fold level of the non-wounded group of the same kind.
Fig. 10. Real-time PCR. Sfrs3 (dot line) and Fn1 (solid line) in weanling airway
mucosal wound 12 h, 24 h and 48 h after wounding. Data were normalized to
the rabbit 18S rRNA of the same specimen, adjusted to a 0-fold level of the
non-wounded group of the same kind, and plotted relative to the level at the
time zero.
H.-S. Li-Korotky et al. / Biochimica et Biophysica Acta 1762 (2006) 34–4542deposition was observed at 1 h–4 h in the fetal wounds
[58,59], suggesting that the regulation of the Fn genes in fetal
skin wounds of this study may occur much earlier.
The opposed expression patterns of Sfrs3 and Fn1 between
fetal and postnatal wounds at 12 h after injury indicate an
importance of the molecular activities of these two genes in
differentiating fetal scarless wound regeneration from postna-
tal scar formation. It is interesting to note that the augmenta-
tions of the postnatal gene expression of both Fn1 and Sfrs3
genes were more prominent in airway mucosal wounds than
that in skin wounds. Our results suggest that the two genes
are involved in the early events of the postnatal airway
mucosal wound repair and that this process is tissue-specific.
Similar expression patterns of the Fn1 and Sfrs3 genes in
both skin and airway mucosal wounds may also indicate that
Fn1 is a potential target of the SRp20 alternative splicing and/
or that the two genes are regulated by conserved regulatory
elements.
4.3. Alternative splicing and SR proteins
4.3.1. Alternative splicing
Alternative splicing of pre-mRNA is a common mechanism
of regulating gene expression and widely recognized to be a
ubiquitous and crucial mechanism for generating protein
diversity and regulating protein expression [60–63]. Bioinfor-
matics analysis of alternative splicing of both human and
mouse data indicates the presence of alternative spliced forms
in up to 80% of human genes [64]. The FN protein diversity
and associated multi-functions are known to be modulated by
alternative splicing [29,30,33,65–68]. Our recent study
showed that the three common domains (EIIIA, EIIIB and V)
of Fn1 that are subjective to alternative splicing were
differentially, selectively included in this model wounds
(manuscript in preparation).
4.3.2. RS domain and SR proteins
Proteins containing arginine/serine-rich (RS) domains play
a fundamental role in coordinating different steps in thesynthesis and processing of pre-mRNA [69]. Serine/arginine-
rich (SR) proteins are believed in alternative splicing of
numerous transcripts because their expression levels can
influence splice site selection. SR proteins have different
specificities for subclasses of pre-mRNAs and the regulation
of the levels of SR proteins in different cell types contributes
to the regulation of cell-specific splice choices [70]. These
proteins act as driving forces during spliceosome assembly and
also play decisive roles in alternative splice-site selection,
suggesting that they are crucial players in the regulation of
splicing during cell differentiation and development [57]. SR
proteins can also influence pre-mRNA processing at the level
of polyadenylation and generally participate in terminal exon
recognition [71]. Therefore, this family of proteins may play a
role in recognition of 3V-terminal exons and perhaps in the
communication between polyadenylation and splicing. Differ-
ent SR proteins have unique intracellular transport properties,
suggesting that SR proteins may have roles not only in nuclear
pre-mRNA splicing but also in mRNA transport, cytoplasmic
events, and/or processes that involve communication between
the nucleus and the cytoplasm [72]. SR proteins are involved
in multi-steps of mRNA metabolism, including nuclear export,
RNA stability, mRNA quality control, and translation [73]. SR
proteins play a crucial role in the selection of FN spliced
domains during development, regeneration, and oncogenesis
[55,56,74].
4.3.3. SRp20 and Fn splicing
Our study demonstrated that Sfrs3, an mRNA encoding
SRp20, was co-expressed with Fn1 gene; induced as early as
12 h and sustained to 48 h post-injury in postnatal airway
mucosal and skin wounds. In fetal wounds, however, the
molecular activity of this gene was either silenced or
suppressed at 12 h post-wounding. SRp20 transcript was up-
regulated within 3 days after peripheral nerve injury [75].
SRp20, a 20-KD SR protein, is widely expressed in multiple
tissues and cell lines [40,76], and is involved in the control of
the early stages of embryonic development [77] and cell cycle
[78]. SRp20 is also a nucleo-cytoplasmic shuttling protein,
promoting the export of intronless RNAs in both mammalian
cells and Xenopus oocytes [79].
Expression of the SR protein SRp40, SRp20, or ASF/SF2
stimulates EIIIB inclusion [56], whereas co-transfection
studies employing cDNAs encoding individual SR proteins
revealed that SRp20 decreased mRNA accumulation in HeLa
cells, whereas SRp40 increased exon EIIIA inclusion in
chondrocytes, but not in HeLa cells [55], suggesting that the
splicing activity of SR proteins is cell-type dependent. In
humans, inclusion or exclusion of the FN-EIIIA exon is
mainly regulated by a polypurinic enhancer element (exonic
splicing enhancer) and a nearby silencer element (exonic
splicing silencer). This is confirmed by RNA–protein
interaction analysis of levels of SR protein binding to each
exon [80]. How a cell achieves the precise tissue-specific
control of an Fn splicing pattern is poorly understood. It is
important to define the high affinity targets of SRp20 and to
evaluate its ability to discriminate between defined RNA
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cellular responses to fetal and postnatal airway mucosal
wound healing.
4.3.4. Fn pre-mRNA splicing and scar formation
Enhanced alternative splicing of FN variants was observed
in cutaneous wounds [81,82]. The expression of EIIIA is
increased in the skin of patients with cutaneous graft-versus-
host disease, suggesting that FN-EIIIA is a marker of skin
fibrosis [83]. Expression of EIIIA and EIIIB spliced variants in
bone indicates that these two splice variants are strong markers
for active fibrogenetic and osteoid-forming processes in human
bones [84]. FN spliced variants containing the EIIIA and/or
EIIIB exons are prominently expressed in the vasculature of a
variety of human tumors but not in normal adult counterpart
[85]. The deletion of the alternatively spliced EIIIA domain in
mice reduces atherosclerosis [86]. Results from previous
studies and our in vivo model of wound healing suggest that
alternative splicing of Fn domains is involved in the multi-steps
of the postnatal wound healing process and associated with
postnatal wound scar formation.
4.4. Regulatory elements of the co-expression of Fn1 and Sfrs3
cDNAs
Previous studies and our data provide evidence that Sfrs3 is
one of the SR proteins that may selectively exclude or include
Fn1 variants [55,56] during wound healing process. However,
such a similar expression pattern of Fn1 and Sfrs3 in our in
vivo model may suggest that during the wounding process,
both genes are transcriptionally regulated by one (or more)
common transcription factor(s). Search for putative promoter-
specific transcription factor binding sites (TFBSs) and tran-
scription factors of each gene might reveal conserved
regulatory elements that are critical for their co-expression
during wound healing. We found that the two genes do not
share a common TFBS. Nevertheless, data from MAPPER
search showed 13 predicted transcription factors that might be
shared by Fn1 and Sfrs3 at the promoter region of each gene.
Increasing evidence suggests that the processes of transcription
and pre-mRNA alternative splicing are tightly coordinated and
promoter and enhancer elements can influence alternative
splicing [80,87]. Functional association between promoter
structure and FN transcript alternative splicing was observed
[88]. During wound healing process, transcription factors/
promoter complexes may be correspondingly altered, resulting
in recruitment and activation of different splicing factors that
function to differentially select Fn spliced domains for the need
of wound repair.
The goal of this manuscript is to demonstrate simultaneous
changes in the expression of a splicing factor and the
expression of Fn by comparison between fetal and postnatal
rabbit airway mucosal and skin wounds. Fn gene regulation is a
very complex process and, obviously, Sfrs3 is not the only
splicing factor for the selections of the Fn variants during
wound healing process. Therefore, the mechanisms of Fn gene
regulation are beyond the scope of this manuscript.5. Conclusion
The mRNA differential display provided a unique tool to
identify candidate genes that may play key roles in fetal
airway mucosal scarless wound healing or postnatal wound
repair. Rabbit serves a valuable model relevant to human
wound repair. Sfrs3, a pre-mRNA splicing factor, and Fn1, a
provisional ECM, were co-expressed in skin and airway
mucosal wounds in vivo. The expression patterns of the two
genes were strikingly different between fetal (suppressed)
and postnatal (induced) wounds and tissue-specific. We
suggest that the molecular activities of Sfrs3 and Fn1 during
the early events of the airway mucosal wound healing
process are crucial in differentiating between fetal wound
regeneration and postnatal scar formation. It is important to
define the high affinity targets of SRp20 and to evaluate its
ability to discriminate between defined RNA targets of the
different isoforms of Fn in the context of the cellular
responses to fetal and postnatal airway mucosal wound
healing.
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